Study of SFA002 in Patients With Mild to Moderate Psoriasis Plaques
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, metabolism and potential effect of drug
product SFA004 on mild to moderate chronic plaque psoriasis. Psoriasis is a common chronic
skin disorder that affects over 4 million people. There is no cure for psoriasis and
treatment is directed at controlling patients' symptoms.
Phase:
Phase 1
Details
Lead Sponsor:
SFA Therapeutics
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins